98%
921
2 minutes
20
Objective: To investigate the correlation of histological prostatitis with sexual function (erectile dysfunction [ED]) and lower urinary tract symptoms (LUTS) in patients with benign prostatic hyperplasia (BPH).
Methods: A retrospective analysis of patients with BPH who received surgical treatment (from May 1, 2012 to November 30, 2012) was conducted, consisting of 80 patients with uncomplicated BPH and 80 patients with BPH plus histological prostatitis. The International Index of Erectile Function (IIEF-5) symptom score and the International Prostate Symptom Score (IPSS) before surgery were calculated. Preoperative sexual functions were compared between the 2 groups.
Results: Differences between both groups in age (72.56 ± 7.36 vs 71.98 ± 7.33) and IPSS score (18.65 ± 5.72 vs 20.50 ± 7.12) were not statistically significant (P >.05). Meanwhile, comparison in erectile function symptom score (14.80 ± 5.93 vs 7.35 ± 4.38) demonstrated significant differences (P <.001). According to the IIEF-5 score, 52 patients had normal erectile function or mild ED, 16 had moderate ED, and 12 had severe ED in the uncomplicated BPH group, whereas 10 patients had mild ED, 32 had moderate ED, 38 had severe ED, and no patients were found normal in BPH within the histological group. Further analysis using the chi-square test demonstrated significant differences between both groups (P <.001).
Conclusion: BPH combined with histological prostatitis had a serious impact on sexual function of the patients. Histological prostatitis may serve as a major risk factor for sexual dysfunction while having little effects on LUTS in patients with BPH.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.urology.2013.06.010 | DOI Listing |
J Neurooncol
September 2025
Department of Neurosurgery, University of Michigan, Ann Arbor, MI, USA.
Purpose: Frailty measures are critical for predicting outcomes in metastatic spine disease (MSD) patients. This study aimed to evaluate frailty measures throughout the disease process.
Methods: This retrospective analysis measured frailty in MSD patients at multiple time points using a modified Metastatic Spinal Tumor Frailty Index (MSTFI).
Lancet Oncol
September 2025
British Columbia Cancer Agency, Vancouver, BC, Canada.
Background: The role of metastasis-directed therapy (MDT) in castration-resistant prostate cancer (CRPC) remains unclear. Prostate Cancer Study 9 (PCS-9) aimed to evaluate the benefits of stereotactic body radiotherapy (SBRT) in addition to standard systemic therapy in patients with oligometastatic CRPC.
Methods: This open-label, randomised, phase 2 trial was conducted across 13 Canadian academic and community oncology centres.
Cancer Discov
September 2025
Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.
Unlabelled: Lineage plasticity, a critical hallmark of cancer progression, enables tumor cells to evade inhibition of primary oncogenic pathways through histologic transformation. This adaptive process, driven by stemness-associated features and epigenetic reprogramming, poses significant challenges in treatment. Using non-small cell lung cancer and prostate cancer as models, we examine the utility of tissue and liquid biopsies in detecting histologic transformations and tailoring treatments to specific subtypes, which has profound clinical implications, potentially improving outcomes in patients with advanced, therapy-resistant disease.
View Article and Find Full Text PDFVirchows Arch
September 2025
Department of Biomedical Science, Humanitas University, Via Rita Levi Montalcini, 4 - 20072, Pieve Emanuele, Milan, Italy.
Gleason pattern 5 (GP5) prostatic adenocarcinoma (PC) includes distinct morphologies: undifferentiated solid pattern (US), solid and cribriform with necrosis (CN), clusters and cords (CC), and isolated single tumour cells (ISTC). The role of these patterns in the metastatic setting is still poorly understood. We conducted a case-control retrospective histological characterization of two cohorts of ISUP Grade Group 5 PC, one with nodal metastases (N1) and one without (N0), comparing GP5 sub-patterns distribution, from robot-assisted radical prostatectomies with extended lymphadenectomy diagnosed between January 2013 and February 2023.
View Article and Find Full Text PDFBr J Nutr
September 2025
Centro de Investigación en Salud Poblacional. LTS: MGP:
To assess the association between dietary consumption patterns of antioxidant and pro-oxidant nutrients with prostate cancer (PC) and its histological differentiation, we analyzed data from 394 histologically confirmed incident cases of PC and 793 age-matched population controls (± 5 years), residents of Mexico City. Cases were classified by Gleason score into well-, moderately-, and poorly differentiated categories. Dietary nutrient intake over the three years preceding diagnosis for cases and before the interview for controls was estimated using a semi-quantitative food frequency questionnaire.
View Article and Find Full Text PDF